Hylton NM - Search Results

1

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Pusztai L, et al. Among authors: hylton nm. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. Cancer Cell. 2021. PMID: 34143979 Free PMC article. Clinical Trial.

2

MRA: how it's done and what it shows.

Hylton NM, Du LN, Winkler M. Hylton NM, et al. Diagn Imaging (San Franc). 1990 Jun;12(6):117, 120-5. Diagn Imaging (San Franc). 1990. PMID: 10149368 Review. No abstract available.

3

Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.

Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Esserman L, et al. J Clin Oncol. 1999 Jan;17(1):110-9. doi: 10.1200/JCO.1999.17.1.110. J Clin Oncol. 1999. PMID: 10458224

4

Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.

Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Kinkel K, et al. Among authors: hylton nm. AJR Am J Roentgenol. 2000 Jul;175(1):35-43. doi: 10.2214/ajr.175.1.1750035. AJR Am J Roentgenol. 2000. PMID: 10882243

5

Integration of breast imaging into cancer management.

Esserman LJ, Wolverton D, Hylton N. Esserman LJ, et al. Curr Oncol Rep. 2000 Nov;2(6):572-81. doi: 10.1007/s11912-000-0112-y. Curr Oncol Rep. 2000. PMID: 11122895 Review.

6

Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Esserman L, Hylton N, George T, Weidner N. Esserman L, et al. Breast J. 1999 Jan;5(1):13-21. doi: 10.1046/j.1524-4741.1999.005001013.x. Breast J. 1999. PMID: 11348250

7

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

8

Magnetic resonance imaging for primary breast cancer management: current role and new applications.

Esserman L, Wolverton D, Hylton N. Esserman L, et al. Endocr Relat Cancer. 2002 Jun;9(2):141-53. doi: 10.1677/erc.0.0090141. Endocr Relat Cancer. 2002. PMID: 12121836 Review.

9

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Partridge SC, et al. Among authors: hylton nm. AJR Am J Roentgenol. 2002 Nov;179(5):1193-9. doi: 10.2214/ajr.179.5.1791193. AJR Am J Roentgenol. 2002. PMID: 12388497

10

Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.

Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Hwang ES, et al. Among authors: hylton nm. Ann Surg Oncol. 2003 May;10(4):381-8. doi: 10.1245/aso.2003.03.085. Ann Surg Oncol. 2003. PMID: 12734086

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page